Treatment with the small molecule PYK2/FAK inhibitor PF-562271 reversed PYK2/FAK signaling activation in recurrent tumors, reducing tumor volume by 43% and increasing animal survival by 33% [21]. This evidence concerns the gene PTK2B and neoplasm.